Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 inhibitor plus metronomic oral vinorelbine for first-line treatment of elderly advanced NSCLC
ChiCTR2300074586Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Beijing Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
vinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300074586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074586.